Instituto de Biología y Medicina Experimental (IBYME)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.
Laboratory of Tissue Plasticity in Health and Disease, Stem Cell and Developmental Biology Cluster, Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
Hum Reprod. 2021 May 17;36(6):1501-1519. doi: 10.1093/humrep/deab053.
What are the effects of plant-derived antioxidant compounds urolithin A (UA) and B (UB) on the growth and pathogenetic properties of an in vitro endometriosis model?
Both urolithins showed inhibitory effects on cell behavior related to the development of endometriosis by differentially affecting growth, adhesion, motility, and invasion of endometriotic cells in vitro.
Endometriosis is one of the most common benign gynecological diseases in women of reproductive age and is defined by the presence of endometrial tissue outside the uterine cavity. As current pharmacological therapies are associated with side effects interfering with fertility, we aimed at finding alternative therapeutics using natural compounds that can be administered for prolonged periods with a favorable side effects profile.
STUDY DESIGN, SIZE, DURATION: In vitro cultures of primary endometriotic stromal cells from 6 patients subjected to laparoscopy for benign pathologies with histologically confirmed endometriosis; and immortalized endometrial stromal (St-T1b) and endometriotic epithelial cells (12Z) were utilized to assess the effects of UA and UB on endometriotic cell properties. Results were validated in three-dimensional (3D) in vitro co-culture spheroids of 12Z and primary endometriotic stroma cells of one patient, and organoids from 3 independent donors with endometriosis.
PARTICIPANTS/MATERIALS, SETTING, METHODS: The effects on cell growth were measured by non-radioactive colorimetric assay to measure cellular metabolic activity as an indicator of cell viability (MTT assay) and flow cytometric cell cycle assay on primary cultures, St-T1b, and 12Z. Apoptosis analyses, the impact on in vitro adhesion, migration, and invasion were evaluated in the cell lines. Moreover, Real-Time Quantitative Reverse Transcription polymerase chain reaction (RT-qPCR) assays were performed on primary cultures, St- T1b and 12Z to evaluate a plausible mechanistic contribution by factors related to proteolysis (matrix metalloproteinase 2, 3 and 9 -MMP2, MMP3, MMP9-, and tissue inhibitor of metalloproteinases -TIMP-1-), cytoskeletal regulators (Ras-related C3 botulinum toxin substrate 1 -RAC1-, Rho-associated coiled-coil containing protein kinase 2 -ROCK2-), and cell adhesion molecules (Syndecan 1 -SDC1-, Integrin alpha V-ITGAV-). Finally, the urolithins effects were evaluated on spheroids and organoids by formation, viability, and drug screen assays.
40 µM UA and 20 µM UB produced a significant decrease in cell proliferation in the primary endometriotic cell cultures (P < 0.001 and P < 0.01, respectively) and in the St-T1b cell line (P < 0.001 and P < 0.05, respectively). In St-T1b, UA exhibited a mean half-maximum inhibitory concentration (IC50) of 39.88 µM, while UB exhibited a mean IC50 of 79.92 µM. Both 40 µM UA and 20 µM UB produced an increase in cells in the S phase of the cell cycle (P < 0.01 and P < 0.05, respectively). The same concentration of UA also increased the percentage of apoptotic ST-t1b cells (P < 0.05), while both urolithins decreased cell migration after 24 h (P < 0.001 both). Only the addition of 5 µM UB decreased the number of St-T1b adherent cells. TIMP-1 expression was upregulated in response to treating the cells with 40 µM UA (P < 0.05). Regarding the 12Z endometriotic cell line, only 40 µM UA decreased proliferation (P < 0.01); while both 40 µM UA and 20 µM UB produced an increase in cells in the G2/M phase (P < 0.05 and P < 0.01, respectively). In this cell line, UA exhibited a mean IC50 of 40.46 µM, while UB exhibited a mean IC50 of 54.79 µM. UB decreased cell migration (P < 0.05), and decreased the number of adherent cells (P < 0.05). Both 40 µM UA and 20 µM UB significantly decreased the cellular invasion of these cells; and several genes were altered when treating the cells with 40 µM UA and 10 µM UB. The expression of MMP2 was downregulated by UA (P < 0.001), and expression of MMP3 (UA P < 0.001 and UB P < 0.05) and MMP9 (P < 0.05, both) were downregulated by both urolithins. Moreover, UA significantly downregulated ROCK2 (P < 0.05), whereas UB treatment was associated with RAC1 downregulation (P < 0.05). Finally, the matrix adhesion receptors and signaling (co)receptors SDC1 and ITGAV were downregulated upon treatment with either UA or UB (P < 0.01 and P < 0.05, respectively in both cases). Regarding the effects of urolithins on 3D models, we have seen that they significantly decrease the viability of endometriosis spheroids (80 µM UA and UB: P < 0.05 both) as well as affecting their area (40 µM UA: P < 0.05, and 80 µM UA: P < 0.01) and integrity (40 µM UA and UB: P < 0.05, 80 µM UA and UB: P < 0.01). On the other hand, UA and UB significantly inhibited organoid development/outgrowth (40 and 80 µM UA: P < 0.0001 both; 40 µM UB: P < ns-0.05-0.001, and 80 µM UB: P < 0.01-0.001-0.001), and all organoid lines show urolithins sensitivity resulting in decreasing viability (UA exhibited a mean IC50 of 33.93 µM, while UB exhibited a mean IC50 of 52.60 µM).
LARGE-SCALE DATA: N/A.
LIMITATIONS, REASONS FOR CAUTION: This study was performed on in vitro endometriosis models.
These in vitro results provide new insights into the pathogenetic pathways affected by these compounds and mark their use as a potential new therapeutic strategy for the treatment of endometriosis.
STUDY FUNDING/COMPETING INTEREST(S): This study was funded EU MSCA-RISE-2015 project MOMENDO (691058). The authors have no conflicts of interest to declare.
植物源性抗氧化化合物尿石素 A(UA)和 B(UB)对体外子宫内膜异位症模型的生长和致病特性有何影响?
两种尿石素均通过影响子宫内膜异位症细胞的生长、黏附、运动和侵袭,显示出对与子宫内膜异位症发展相关的细胞行为的抑制作用。
子宫内膜异位症是育龄妇女最常见的良性妇科疾病之一,其定义是子宫内膜组织位于子宫腔外。由于目前的药物疗法与干扰生育能力的副作用有关,我们旨在寻找替代疗法,使用天然化合物,可以在较长时间内以有利的副作用谱进行给药。
研究设计、规模、持续时间:对 6 名因良性疾病接受腹腔镜检查的患者的原代子宫内膜异位症基质细胞进行体外培养,这些患者的组织学证实存在子宫内膜异位症;并利用永生化子宫内膜基质(St-T1b)和子宫内膜异位症上皮细胞(12Z)来评估 UA 和 UB 对子宫内膜异位症细胞特性的影响。在一名患者的 12Z 和原代子宫内膜异位症基质细胞的三维(3D)体外共培养球体以及 3 个独立来源的子宫内膜异位症供体的类器官中验证了结果。
参与者/材料、设置、方法:使用非放射性比色法测量细胞生长,通过测量细胞代谢活性(MTT 测定法)和原发性培养物、St-T1b 和 12Z 的流式细胞周期分析来测量细胞活力。在细胞系中评估细胞凋亡分析、体外黏附、迁移和侵袭的影响。此外,还对原发性培养物、St-T1b 和 12Z 进行实时定量逆转录聚合酶链反应(RT-qPCR)检测,以评估与蛋白水解(基质金属蛋白酶 2、3 和 9-MMP2、MMP3、MMP9-和金属蛋白酶组织抑制剂-1-TIMP-1-)、细胞骨架调节剂(Ras 相关 C3 肉毒毒素底物 1-RAC1-、Rho 相关卷曲螺旋蛋白激酶 2-ROCK2-)和细胞黏附分子(Syndecan 1-SDC1-、整合素 alpha V-ITGAV-)相关的因素的潜在机制贡献。最后,通过形成、活力和药物筛选测定法评估尿石素对球体和类器官的影响。
40μM UA 和 20μM UB 分别使原发性子宫内膜异位症细胞培养物(P<0.001 和 P<0.01)和 St-T1b 细胞系(P<0.001 和 P<0.05)的细胞增殖显著减少。在 St-T1b 中,UA 表现出 39.88μM 的平均半最大抑制浓度(IC50),而 UB 表现出 79.92μM 的平均 IC50。40μM UA 和 20μM UB 均使 St-T1b 细胞周期的 S 期细胞百分比增加(P<0.01 和 P<0.05)。相同浓度的 UA 还增加了 ST-t1b 细胞的凋亡百分比(P<0.05),而两种尿石素均减少了 24 小时后的细胞迁移(P<0.001 均)。只有添加 5μM UB 减少了 St-T1b 附着细胞的数量。UA 处理后 TIMP-1 表达增加(P<0.05)。关于 12Z 子宫内膜异位症细胞系,只有 40μM UA 减少了增殖(P<0.01);而 40μM UA 和 20μM UB 均使 G2/M 期的细胞百分比增加(P<0.05 和 P<0.01)。在该细胞系中,UA 表现出 40.46μM 的平均 IC50,而 UB 表现出 54.79μM 的平均 IC50。UB 减少细胞迁移(P<0.05),并减少附着细胞的数量(P<0.05)。40μM UA 和 20μM UB 均显著降低这些细胞的细胞侵袭;并且在用 40μM UA 和 10μM UB 处理细胞时,几个基因发生了改变。UA 显著下调 MMP2 的表达(P<0.001),而 MMP3(UA P<0.001 和 UB P<0.05)和 MMP9(P<0.05,两者)的表达均下调由两种尿石素下调。此外,UA 显著下调 ROCK2(P<0.05),而 UB 处理与 RAC1 下调有关(P<0.05)。最后,基质黏附受体和信号(共)受体 SDC1 和 ITGAV 在接受 UA 或 UB 处理时下调(P<0.01 和 P<0.05,在两种情况下均)。
关于尿石素对 3D 模型的影响,我们已经看到它们显著降低子宫内膜异位症球体的活力(80μM UA 和 UB:P<0.05 均),以及影响它们的面积(40μM UA:P<0.05,和 80μM UA:P<0.01)和完整性(40μM UA 和 UB:P<0.05,80μM UA 和 UB:P<0.01)。另一方面,UA 和 UB 显著抑制类器官的发育/生长(40 和 80μM UA:P<0.0001 均;40μM UB:P<ns-0.05-0.001,和 80μM UB:P<0.01-0.001-0.001),所有类器官系均对尿石素敏感,导致活力降低(UA 表现出 33.93μM 的平均 IC50,而 UB 表现出 52.60μM 的平均 IC50)。
无。
局限性、谨慎的原因:本研究在体外子宫内膜异位症模型上进行。
这些体外结果提供了对这些化合物影响的发病途径的新见解,并将其作为治疗子宫内膜异位症的潜在新治疗策略。
研究资金/利益冲突:本研究由欧盟 MSCA-RISE-2015 项目 MOMENDO(691058)资助。作者没有利益冲突。